Abstract
Purpose
Neuroendocrine carcinomas (NECs) are a rare subgroup of neuroendocrine neoplasms that occasionally originate from gastro-entero-pancreatic (GEP) tract. Evidence of the effectiveness of chemotherapy is scarce. Platinum plus Etoposide regimens are currently the standard treatment in first-line, while little data are available on second-line treatments. The aim of this study is to evaluate the efficacy and safety of irinotecan (IRI)-based chemotherapy in a series of extrapulmonary NECs.
Methods
Patients with NEC diagnosis treated at University Hospitals of Modena, Florence, Pisa, and European Institute of Oncology of Milan with an IRI-based regimen (FOLFIRI or XELIRI) after progression to a first-line platinum-based therapy were enrolled. Objective responses were assessed according to RECIST criteria. Progression-free survival (PFS) and overall survival (OS) were calculated.
Results
Thirty-four patients, 16 males, and 18 females, median age of 59 years (range 32–77), with metastatic NEC were included. Twenty-seven patients had Ki-67 ≥ 55% and four patients Ki-67 of <55% (for three patients data were not available). The median number of treatment cycles of the IRI-based regimen was 7.5 (range 1–16). Six partial responses (17.6%) and 9 stable diseases (26.5%) were observed, with a disease control rate of 44.1%. Median PFS and OS were 4.4 and 5.9 months, respectively. Neutropenia, anemia, and nausea were the only G3–G4 toxicities reported.
Conclusions
Despite the relatively small sample size, IRI-based therapy demonstrated to be a valid option for patients with pretreated extrapulmonary NEC.
Similar content being viewed by others
Data availability
The data sets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
References
R. Garcia-Carbonero et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann. Oncol. 21, 1794–1803 (2010)
G. Rindi et al. TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J. Natl Cancer Inst. 104, 764–777 (2012)
J. Strosberg et al. Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. Hum. Pathol. 40, 1262–1268 (2009)
H. Sørbye et al. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer 120, 2814–2823 (2014)
C.G. Moertel et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68, 227–232 (1991)
O. Hentic et al. FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3. Endocr. Relat. Cancer 19, 751–757 (2012)
T. Yamaguchi et al. Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system. Cancer Sci. 105, 1176–1181 (2014)
S. Welin et al. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer 117, 4617–4622 (2011)
I.H. Olsen, et al. Temozolomide as second or third-line treatment of patients with neuroendocrine carcinomas. Sci. World J. 2012, 170496 (2012)
J. Hadoux et al. Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma. Endocr. Relat. Cancer 22, 289–298 (2015)
CTCAE v5.0, Common Terminology Criteria for Adverse Events (CTCAE v5.0). 2017. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf
S. Munker et al. EpiCO (epirubicin, cyclophosphamide, and vincristine) as treatment for extrapulmonary high-grade neuroendocrine neoplasms. Z. Gastroenterol. 58(2), 133–136 (2020)
H. Sørbye et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann. Oncol. 24, 152–160 (2013)
K. Sugiyama et al. Salvage chemotherapy by FOLFIRI regimen for poorly differntiated gastrointestinal neuroendocrine carcinoma. J. Gatrointest. Cancer 2020 https://doi.org/10.1007/s12029-020-00516-7 (Epub ahead of print)
Author information
Authors and Affiliations
Contributions
Material preparation and analysis were performed by C.B., F.G., and A.S. The first draft of the paper was written by C.B. and F.G. and all authors commented on previous versions of the paper. All authors read and approved the final paper.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The studies were approved by the regional ethic committee. This study has the following ethic number: 473/2020.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Bardasi, C., Spallanzani, A., Benatti, S. et al. Irinotecan-based chemotherapy in extrapulmonary neuroendocrine carcinomas: survival and safety data from a multicentric Italian experience. Endocrine 74, 707–713 (2021). https://doi.org/10.1007/s12020-021-02813-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-021-02813-y